Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 6/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21301102 | 0.86 | L3MBTL1 (0.43) | L3MBTL1KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL3498031 | 0.86 | L3MBTL1 (0.44) | L3MBTL1KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL3497547 | 0.86 | L3MBTL1 (0.44) | L3MBTL1KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL3497808 | 0.86 | L3MBTL1 (0.44) | L3MBTL1KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL3496509 | 0.86 | KMT2A (0.52) | KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL2888789 | 0.85 | L3MBTL1 (0.47) | L3MBTL1KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL3498730 | 0.84 | L3MBTL1 (0.43) | L3MBTL1KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL21749176 | 0.83 | L3MBTL1 (0.46) | L3MBTL1KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL4569993 | 0.83 | L3MBTL1 (0.42) | L3MBTL1KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL550869 | 0.83 | L3MBTL1 (0.46) | L3MBTL1KMT2ANPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | ACACA, CPT1B, PC | L3MBTL1 1920/4885KMT2A 3284/4885NPC1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.